Mutant p53 as a Therapeutic Target: The Report of Its Death Was an Exaggeration

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The TP53 gene is frequently mutated in human cancers, with mutant p53 often exhibiting oncogenic gain-of-function properties.
• Mutant p53 has been considered a potential therapeutic target due to its role in cancer progression.

Purpose of the Study:

• To evaluate the therapeutic potential of targeting mutant p53 in cancer.
• To reconcile conflicting findings regarding the impact of mutant p53 removal on tumor therapy.

Main Methods:

• Analysis of recent studies investigating CRISPR-mediated mutagenesis for mutant p53 removal.
• Examination of experimental limitations in previous studies, including recapitulating gain-of-function events and statistical power.
• Review of independent studies on the TP53 Y220C hotspot mutation and its murine homolog.

Main Results:

• A recent CRISPR-based study suggested mutant p53 removal had no therapeutic value, but this may be due to experimental limitations.
• Independent research provides compelling evidence that mutant p53 is a valid therapeutic target.
• Specific strategies targeting mutant p53, such as protein stabilization or inhibition of inflammatory effects, show promise.

Conclusions:

• Despite some conflicting data, targeting mutant p53 represents a viable therapeutic strategy in oncology.
• Developing drugs to restore wild-type p53 function or inhibit mutant p53-associated inflammation holds significant therapeutic potential.